Cargando…
Preferential Antibody and Drug Conjugate Targeting of the ADAM10 Metalloprotease in Tumours
SIMPLE SUMMARY: ADAM10 is a cell surface protein that releases other proteins from cells, thereby controlling a range of functions during normal development. Its activity is normally tightly regulated, but it can become deregulated in cancer calls. We previously showed that an active form of ADAM10...
Autores principales: | Yan, Hengkang, Vail, Mary E., Hii, Linda, Guo, Nancy, McMurrick, Paul J., Oliva, Karen, Wilkins, Simon, Saha, Nayanendu, Nikolov, Dimitar B., Lee, Fook-Thean, Scott, Andrew M., Janes, Peter W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264901/ https://www.ncbi.nlm.nih.gov/pubmed/35804938 http://dx.doi.org/10.3390/cancers14133171 |
Ejemplares similares
-
An activated form of ADAM10 is tumor selective and regulates cancer stem-like cells and tumor growth
por: Atapattu, Lakmali, et al.
Publicado: (2016) -
Fully human monoclonal antibody targeting activated ADAM10 on colorectal cancer cells
por: Saha, Nayanendu, et al.
Publicado: (2023) -
Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells
por: Saha, Nayanendu, et al.
Publicado: (2021) -
ADAM metalloproteases and EGFR signalling
por: Gee, Julia MW, et al.
Publicado: (2003) -
The Effect of Diabetes on the Perioperative Outcomes of Colorectal Cancer Surgery Patients
por: Yap, Raymond, et al.
Publicado: (2016)